CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Non-Hodgkin Lymphoma.

Former Alexion VP pleads guilty to insider trading on Portola buyout

A former Alexion executive confessed to insider trading by sharing confidential company information in 2020 during a criminal hearing at a New York federal court

September 19, 2023

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon

August 8, 2023

Drinking more water may lower heart disease risk, but too much coffee and tea could raise it

Drinking water may help reduce cardiovascular disease (CVD) risk, while excessive coffee and tea intake (≥6 cups/day) increases the likelihood of CVD, with stronger effects

February 19, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.